Navigation Links
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
Date:2/15/2013

5 years
  • Related Milestones/catalysts in 2013-14
  • Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.
  • Ongoing Clinical Trials of Companies Covered
  • Detailed reports on
  • SymBio pharma (4582, ¥488)

    Curis (CRIS, $2.99)

    Gilead (GILD, $40.36)

    Pharmacyclics (PCYC, $69.28) -

    Infinity pharma (INFI, $35.02)

    Request for Sample pages - http://www.bharatbook.com/RequestSample.asp?pid=372901

    Table of Contents

    Executive Summary

    Drugs in the Pipeline

    Phosphoinositide 3-Kinases (PI3Ks) inhibitors

    Scientific Rationale

    Dual inhibitors

    Bruton's Tyrosin Kinase (BTK) Inhibitors

    Scientific Rationale

    BTK inhibitors - Pipeline

    M&A to Follow - Kinase inhibitors have attracted partnering deals at a premium

    Kinase Inhibitor: Select M&A / Deals

    Upcoming Milestones Related in 2013-14

    Combination Studies - PI3K, BTK + Rituxan/ Bendamustine

    Idelalisib (GS-1101) - Clinical Data

    Rigosertib - Clinical Data

    Other PI3K or Dual Inhibitors - Clinical Data

    Combination Studies of
    '/>"/>

    SOURCE Bharat Book Bureau
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Womens Health Expert GC-Rise Ties up with Georgetown MBA Team to Tap M&A Potential and Growth Strategy
    2. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
    3. Kinase Inhibitors: Global Markets -- Focus on the U.S.
    4. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
    5. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
    6. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... SAN DIEGO and BETHESDA, ... announced today that they are joining together with ... (NIH) to help scientists develop more reliable tools ... on a faster timeline. Organovo is collaborating with ... and the National Eye Institute (NEI) to develop ...
    (Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation ... discovering, developing and commercializing innovative therapies addressing ... today announced that it received the Notice ... and Trademark Office on its unique self-delivering ... fibrosis. The patent covers the use of ...
    (Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ... staff,” said Dr. Andrew Brown, SPIE Senior Director for ...
    (Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ... called WebBytez . WebBytez is a patent-pending way ...
    Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
    ... becoming increasingly flatter - some have even become almost as ... dimensions, much to the delight of home cinema fans. Cellphones ... All of these developments owe their thanks to miniature light-emitting ... multitude of devices. However, LED technology does have a ...
    ... 16 Accuray Incorporated (Nasdaq: ARAY ), a global leader in ... at the Wells Fargo Securities Healthcare Conference in Boston on ... PT . , , , ... the presentation will be available online from the investor relations page of the ...
    ... Trans World Alloys (TWA), one of the country,s premier titanium sheet ... joined the company, as its new Chief Operating Officer. ACCORDING TO SANDY SHADROW, ... the metal business in a variety of areas." , ... Ed has attended the University of Baltimore , the ...
    Cached Biology Technology:World of lights in the microcosmos 2Accuray Incorporated to Speak at Wells Fargo Securities Healthcare Conference 2Ed Brennan - New C.O.O. of Trans World Alloys 2
    (Date:4/16/2014)... and soil processes are to blame for significant baseline ... a study published recently in the Journal of ... samples from all corners of Ohio showed that every ... of concern recommended by the U.S. Environmental Protection Agency. ... authors, who note that regulatory levels typically are set ...
    (Date:4/16/2014)... Leo Heim and their colleagues at the University of ... of generating hydrogen using water and formaldehyde. The generation ... it comes to fuel cell technologies. The results of ... water and formaldehyde", have recently been published in the ... the new approach can be used to recycle industrial ...
    (Date:4/15/2014)... Calif. UC Irvine neurobiologists have found that genetically ... into the brains of mice with the symptoms and ... in the journal Stem Cells Research and Therapy ... in two different mouse models. , Alzheimer,s disease, ... associated with accumulation of the protein amyloid-beta in the ...
    Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
    ... 2010) When researchers tested three different labeling agents ... effect the labeling agents had on stem cell phenotype, ... stem cell proliferation depending on the type of contrast ... and Spain tested USPIO (ultra small superparamagnetic iron oxide) ...
    ... voracious predatory crabs due to global warming could threaten ... published findings. "King crabs are ecologically important ... fisheries," said Dr Sven Thatje, an evolutionary ecologist at ... Science (SOES), which is based at the National Oceanography ...
    ... to spot prey, vision keeps many animals, including humans, alive. ... is it easier for us to spot movement of small ... things? The complexity of the neural network that supports vision ... and support from the National Science Foundation, Claire Wyart in ...
    Cached Biology News:MRI contrast agents change stem cell proliferation 2King crab distributions limited by temperature in the Southern Ocean 2The zebrafish's neural circuit prevents it from biting off more than it can chew 2
    PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
    IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
    Request Info...
    RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
    Biology Products: